Key result
The IGFBP-3/IGFBP-3R system is dysregulated in obesity due to neutrophil serine protease-induced proteolysis, suggesting therapeutic potential for IGFBP-3R agonists and NSP inhibitors in insulin resistance.
The NSP/IGFBP-3/IGFBP-3R axis plays a critical role in obesity-associated insulin resistance and may serve as a novel therapeutic target.
Hypothesis-generating for IGFBP-3R agonists and NSP inhibitors in insulin resistance; leaves open confirmation in prospective trials.
No takes yet. Share an insight, caveat, or question.
Youngman Oh (2020) conducted a review in Obesity-associated Insulin Resistance. IGFBP-3/IGFBP-3R system was evaluated. The IGFBP-3/IGFBP-3R system is dysregulated in obesity due to neutrophil serine protease-induced proteolysis, suggesting therapeutic potential for IGFBP-3R agonists and NSP inhibitors in insulin resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: